Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C. , March 16, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO

Three ways to be healthy for National Nutrition Month

March is National Nutrition Month® and the theme for this year is “Beyond the Table.” That theme makes us recall the phrase “thinking outside of the box.” So what does that mean? Thinking outside of the box implies breaking free of physical or invisible constraints, traditions and rules. It’s about embracing innovative, creative ideas and using your imagination to explore new ways of doing things instead of doing what’s expected or what’s been done in the past. 

Labcorp Launches Weight Loss Management Testing Solutions

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C. , March 7, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services,

Addressing Challenges with Ulcerative Colitis Clinical Study Recruitment

We understand the significant challenges sponsors face with patient recruitment in their ulcerative colitis (UC) clinical studies. While the prevalence of UC is relatively high (~0.2% in North America, Oceania and much of Europe – and rising in urbanized/industrialized countries in Africa, Asia and Latin America1), recruitment rates into clinical studies are woefully low. Achieving a linear average recruitment rate of just 0.1 patients/site/month* is considered the standard (*calculated by dividing total patient accrual by number of sites by overall recruitment window [months]).

The role of B-cell cloning in the generation of antibody critical reagents: apoptosis-related antigen case study

B-cell cloning, a recent improvement over typical hybridoma technology, is becoming an industry standard tool for the reliable and reproducible production of monoclonal antibodies. Read on to find out how we have successfully utilized B-cell cloning to produce antibody critical reagents, for a recombinant protein, and to learn how this service offering can help you by supplying antibody critical reagents specific to your clinical development needs.1,2

Non-GLP sample analysis for ocular biodistribution studies

Traditional bioanalytical service providers are geared toward analyzing large sets of samples under various regulatory guidelines, such as large nonclinical and clinical studies, which are heavily regulated. This puts a heavy burden on these service providers, creating long lead times, resource constraints and lack of flexibility. Currently, many bioanalytical laboratories report lead times of six to nine months to begin development work. These limited bioanalytical options are causing extensive delays in overall drug development affecting the finances of sponsors.

New OECD TG 497: Interpretation and application of defined approaches for skin sensitization assessment

The advent of requiring multiple non-animal in vitro alternatives for skin sensitization assessments has prompted the Organisation for Economic Co-operation and Development (OECD) to publish new guidance to outline the approaches for data interpretation from multiple non-animal test methods. When used together in specific combinations, these methods will aid with skin sensitization hazard identification and, potentially, potency characterization. A detailed scientific understanding of how best to apply these methods and/or test strategies is needed to address the requirements of regulators for different test chemicals (molecules, chemicals, substances, etc.). This blog will provide an overview of these defined approaches (DAs).